Lundbeck Pharms Llc Drug Patent Portfolio

Lundbeck Pharms Llc owns 1 orange book drug protected by 7 US patents Given below is the list of Lundbeck Pharms Llc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11529357 Injectable carbamazepine composition essentially free of 10-bromo-carbamazepine 31 Jan, 2040
Active
US9493582 Alkylated cyclodextrin compositions and processes for preparing and using the same 27 Feb, 2033
Active
US7635773 Sulfoalkyl ether cyclodextrin compositions 13 Mar, 2029
Active
US8410077 Sulfoalkyl ether cyclodextrin compositions 13 Mar, 2029
Active
US9750822 Sulfoalkyl ether cyclodextrin compositions 13 Mar, 2029
Active
US9629797 Parenteral carbamazepine formulation 10 Nov, 2028
Active
US9770407 Parenteral carbamazepine formulation 10 Nov, 2028
Active


Given below is the list of recent legal activities going on the following drug patents of Lundbeck Pharms Llc.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 30 Apr, 2024 US9493582
Post Issue Communication - Certificate of Correction 08 Feb, 2023 US11529357
Recordation of Patent Grant Mailed 20 Dec, 2022 US11529357
Patent Issue Date Used in PTA Calculation 20 Dec, 2022 US11529357
Correspondence Address Change 04 Dec, 2022 US9750822
Correspondence Address Change 04 Dec, 2022 US8410077
Correspondence Address Change 04 Dec, 2022 US9493582
Correspondence Address Change 04 Dec, 2022 US7635773
Email Notification 01 Dec, 2022 US11529357
Issue Notification Mailed 30 Nov, 2022 US11529357
Application Is Considered Ready for Issue 16 Nov, 2022 US11529357
Dispatch to FDC 16 Nov, 2022 US11529357
Issue Fee Payment Received 14 Nov, 2022 US11529357
Issue Fee Payment Verified 14 Nov, 2022 US11529357
Electronic Review 21 Oct, 2022 US11529357


Lundbeck Pharms Llc's Drug Patent Litigations

Lundbeck Pharms Llc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 03, 2014, against patent number US9629797. The petitioner , challenged the validity of this patent, with James Cloyd et al as the respondent. Click below to track the latest information on how companies are challenging Lundbeck Pharms Llc's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US9770407 December, 2014 Decision
(15 Mar, 2017)
Lundbeck Pharmaceuticals LLC
US9629797 July, 2014 Decision
(15 Dec, 2016)
James Cloyd et al


Lundbeck Pharms Llc Drug Patents' Oppositions Filed in EPO

Lundbeck Pharms Llc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 06, 2015, by Actavis Group Ptc Ehf. This opposition was filed on patent number EP06816054A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP06816054A Feb, 2015 Actavis Group PTC ehf Revoked


Lundbeck Pharms Llc's Family Patents

Lundbeck Pharms Llc drugs have patent protection in a total of 21 countries. It's US patent count contributes only to 30.3% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Lundbeck Pharms Llc Drug List

Given below is the complete list of Lundbeck Pharms Llc's drugs and the patents protecting them.


1. Carnexiv

Carnexiv is protected by 7 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11529357 Injectable carbamazepine composition essentially free of 10-bromo-carbamazepine 31 Jan, 2040
(15 years from now)
Active
US9493582 Alkylated cyclodextrin compositions and processes for preparing and using the same 27 Feb, 2033
(8 years from now)
Active
US7635773 Sulfoalkyl ether cyclodextrin compositions 13 Mar, 2029
(4 years from now)
Active
US8410077 Sulfoalkyl ether cyclodextrin compositions 13 Mar, 2029
(4 years from now)
Active
US9750822 Sulfoalkyl ether cyclodextrin compositions 13 Mar, 2029
(4 years from now)
Active
US9629797 Parenteral carbamazepine formulation 10 Nov, 2028
(4 years from now)
Active
US9770407 Parenteral carbamazepine formulation 10 Nov, 2028
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Carnexiv's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List